Meeting
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
Authors
Christopher David Walden
Gundersen Lutheran Health System Inc., La Crosse, WI
Christopher David Walden , Samuel Mosiman , Andrew J. Borgert , Benjamin Marshall Parsons
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 544)
DOI
10.1200/JCO.2022.40.16_suppl.544
Abstract #
544
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Simulation modeling of the effects of adjuvant chemotherapy in early-stage breast cancer.
First Author: Jinani Jayasekera
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer
Poster
2023 ASCO Annual Meeting
Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.
First Author: Leticia Campoverde
Poster
2022 ASCO Annual Meeting
Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET).
First Author: Adam Brufsky